×

Nucleic acid vaccines

  • US 10,709,779 B2
  • Filed: 07/27/2018
  • Issued: 07/14/2020
  • Est. Priority Date: 04/23/2014
  • Status: Active Grant
First Claim
Patent Images

1. A method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more messenger ribonucleic acid (mRNA) polynucleotides comprising an open reading frame encoding an antigenic polypeptide that is derived from an infectious agent, wherein the mRNA polynucleotide is not self-replicating RNA, wherein the mRNA polynucleotides are formulated within a cationic lipid nanoparticle having a molar ratio of about 20-60% ionizable cationic lipid:

  • about 5-25% non-cationic lipid;

    about 25-55% sterol; and

    about 0.5-15% PEG-modified lipid, wherein the nucleic acid vaccine elicits an immune response having a longer lasting antibody titer than an antibody titer elicited by a reference nucleic acid vaccine comprising the one or more mRNA polynucleotides not formulated within a cationic lipid nanoparticle having a molar ratio of about 20-60% ionizable cationic lipid;

    about 5-25% non-cationic lipid;

    about 25-55% sterol; and

    about 0.5-15% PEG-modified lipid.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×